BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Targepeutics, Inc. Announces Patent License Agreement With National Institutes of Health (NIH)


10/19/2005 5:09:09 PM

HERSHEY, Pa., Aug. 17 /PRNewswire/ -- Targepeutics, Inc. announces that the company has entered into a license agreement with the National Institutes of Health (NIH) for commercial rights to ten US patents: Nos. 5, 614,191; 5,919,456; 6,518,061; 4,892,827; 5,696,237; 5,863,745; 6,051,405; 5,705,156; 5,512,658 and 5,328,984. Combined with Targepeutics' other exclusively licensed issued patents and several pending applications, these additionally patents give Targepeutics broad rights to commercialize its Genetically Engineered Interleukin 13 (IL-13) platform. The agreement was negotiated under the lead counsel of Jorge Goldstein of Sterne Kessler Goldstein & Fox PLLC.

The patents licensed from the NIH provide certain background rights for Targepeutics' Genetically Engineered IL-13 platform that includes its lead compound, Glioblast-13, a singly mutated IL-13 molecule combined with a derivative of Pseudomonas exotoxin. Glioblast-13 and further generations of mutated IL-13 of the entire platform were designed to be more specific, safe and potent than the wild type-based IL-13 compounds. Comparative studies performed to date have shown that the mutated IL-13 compounds have a safer and more potent therapeutic profile than wild type IL-13 based compounds.

Targepeutics' Genetically Engineered IL-13 platform is expected to yield more specific compounds with multiple mutations of the IL-13 molecule described in the recently issued patents. This platform will explore products for both therapeutic and diagnostic applications. The specificity and safety profile to date of these mutants opens up the possibility of treating cancers expressing the IL-13 receptor alpha 2, such as brain, pancreatic, head and neck, melanoma and gastric cancers. Targepeutics envisions using the targeting mutated IL-13's to carry cytotoxins or radiation to these cancers. These applications are currently hampered by the nonspecific nature of wild type IL- 13 based compounds that appear to target vital organs as well as tumors.

Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight cancer. Currently, Targepeutics' three pharmaceutical platforms are Targepeutics' Genetically Engineered Interleukin-13, Immunotherapy (applications in cancer and asthma), and Anti- tumor Progression (targeting growth and ability of solid tumors to create new blood vessels). Targepeutics is based in Hershey, Pennsylvania and is privately held.

For more information, please contact: Sil Lutkewitte, President, at slutkewitte@targepeutics.com

Targepeutics, Inc.

CONTACT: Sil Lutkewitte, President of Targepeutics, Inc., +1-717-533-7772,or slutkewitte@targepeutics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES